Publications by authors named "W B STANTON"
Optimal therapeutic approaches for advanced Langerhans cell histiocytosis (LCH) are not known. We assessed the safety and efficacy of combined chemotherapy with MAPK pathway inhibition in 10 patients with refractory systemic disease and/or LCH-associated neurodegeneration. Overall response rate was 9/10 (90%) for the entire cohort: 5/5 (100%) for patients with systemic disease and 6/7 (86%) for patients with central nervous system disease.
View Article and Find Full Text PDFOver 50% of patients with systemic LCH are not cured with front-line therapies, and data to guide salvage options are limited. We describe 58 patients with LCH who were treated with clofarabine. Clofarabine monotherapy was active against LCH in this cohort, including heavily pretreated patients with a systemic objective response rate of 92.
View Article and Find Full Text PDFArticle Synopsis
- Traditional culture methods for identifying infections in penile prostheses (PPs) result in a high rate of culture-negative outcomes, while next-generation sequencing (NGS) shows significantly higher detection rates of microorganisms.
- Ninety-one explanted PPs were analyzed using both culture and NGS methods, with NGS identifying 79.1% of microbial isolates compared to only 3.3% from culture methods.
- The findings suggest that NGS is more effective in identifying a greater variety of pathogens, which could improve tailored antimicrobial treatment and patient outcomes in the future.
Men treated with androgen deprivation therapy for rising PSA after failed local therapy will often develop castrate resistance, and the appearance of metastases predicts a poor prognosis. Thus, researchers have long sought to prolong the onset of metastasis in patients with nonmetastatic castration-resistant prostate cancer (CRPC). Until 2018, patients in this group had no FDA-approved treatment options.
View Article and Find Full Text PDFIntroduction: To identify patients at risk of high-grade prostate cancer using prostate cancer biomarkers.
Materials And Methods: A total of 601 men were screened for prostate cancer in 2012, 2015, and 2016 using prostate cancer biomarkers: prostate health index (phi), 4KScore, and SelectMDx. The first two are blood tests that incorporate several PSA isoforms; SelectMDx measures mRNA levels of homeobox C6 and distal-less homeobox 1 in post-digital rectal examination urine samples.